| Literature DB >> 29937833 |
Abstract
Electrically evoked compound action potential (eCAP) amplitudes elicited at suprathreshold levels were assessed as a measure of the effectiveness of cochlear implant (CI) stimulation. Twenty-one individuals participated; one was excluded due to facial stimulation during eCAP testing. For each participant, eCAPs were elicited with stimulation from seven electrodes near the upper limit of the individual's electrical dynamic range. A reduced-channel CI program was created using those same seven electrodes, and participants performed a vowel discrimination task. Consistent with previous reports, eCAP amplitudes varied across tested electrodes; the profiles were unique to each individual. In 6 subjects (30%), eCAP amplitude variability was partially explained by the impedance of the recording electrode. The remaining amplitude variability within subjects, and the variability observed across subjects could not be explained by recording electrode impedance. This implies that other underlying factors, such as variations in neural status across the array, are responsible. Across-site mean eCAP amplitude was significantly correlated with vowel discrimination scores (r2 = 0.56). A single eCAP amplitude measured from the middle of the array was also significantly correlated with vowel discrimination, but the correlation was weaker (r2 = 0.37), though not statistically different from the across-site mean. Normalizing each eCAP amplitude by its associated recording electrode impedance did not improve the correlation with vowel discrimination (r2 = 0.52). Further work is needed to assess whether combining eCAP amplitude with other measures of the electrode-neural interface and/or with more central measures of auditory function provides a more complete picture of auditory function in CI recipients.Entities:
Keywords: Cochlear implant; Compound action potential; Suprathreshold amplitude
Year: 2017 PMID: 29937833 PMCID: PMC6011805 DOI: 10.1016/j.joto.2017.01.001
Source DB: PubMed Journal: J Otol ISSN: 1672-2930
Participant information.
| ID | Age (yrs) | Sex | Test ear | Reported etiology | Internal device | Age at IS (yrs) | Months post IS | Vowel (%) | Year tested |
|---|---|---|---|---|---|---|---|---|---|
| E40R | 50 | M | R | Otosclerosis | 24RE | 44 | 79 | 54 | 2013 |
| E51 | 27 | F | R | Pendred, progressive | 24RE | 26 | 15 | 29 | 2013 |
| E55R | 63 | F | R | Genetic? | 24RE | 57 | 74 | 49 | 2013 |
| E60 | 86 | F | R | Unknown | 24RE | 80 | 65 | 50 | 2012 |
| E68L | 57 | F | L | Unknown | 24RE | 52 | 62 | 38 | 2013 |
| F18R | 66 | F | R | Meniere's? | CI512 | 63 | 28 | 35 | 2013 |
| F19R | 78 | M | R | Unknown | CI512 | 76 | 27 | 29 | 2012 |
| F25R | 60 | F | R | Genetic | CI512 | 57 | 36 | 27 | 2013 |
| F26L | 53 | F | L | Unknown | CI512 | 51 | 22 | 65 | 2013 |
| F2L | 58 | M | L | Congenital, progressive | CI512 | 55 | 35 | 38 | 2013 |
| F8R | 70 | F | R | Unknown | CI512 | 68 | 26 | 24 | 2013 |
| E18 | 78 | M | R | Noise exposure | 24RE | 68 | 120 | 38 | 2015 |
| E22 | 82 | M | R | Noise exposure | 24RE | 72 | 119 | 35 | 2015 |
| E58 | 58 | M | L | Meniere's? | 24RE | 50 | 99 | 56 | 2015 |
| E83R | 75 | M | R | Unknown | 24RE | 69 | 78 | 36 | 2015 |
| E89R | 70 | F | R | Otosclerosis | 24RE | 64 | 69 | 67 | 2015 |
| E97L | 71 | M | L | Noise exposure | 24RE | 67 | 45 | 32 | 2015 |
| E101R | 79 | M | R | Genetic? | 24RE | 77 | 25 | 37 | 2015 |
| E105L | 64 | M | L | Noise exposure | 24RE | 57 | 83 | 42 | 2016 |
| F10L | 63 | F | L | (Progressive) | CI512 | 58 | 60 | 58 | 2016 |
| F13L | 63 | M | L | Labyrinthitis | CI512 | 57 | 66 | 32 | 2015 |
Identifier (ID); Initial Stimulation (IS).
F2L and E51 had childhood onset hearing loss that progressively worsened. Both were pediatric hearing aid users. All other participants had histories consistent with post-lingual onset hearing loss.
Participant was excluded due to facial nerve stimulation to high-level eCAP stimuli. Recordings were obtained, but stimulation was below the desired level.
Fig. 1Suprathreshold eCAP amplitude profiles for each participant (identifier is displayed in the lower right corner of each panel). Amplitudes were normalized to each participant's maximum (see number in parentheses) for plotting purposes. The panels are ordered by the across-site means of the eCAP amplitudes. Electrode position is displayed on the abscissa; the numbering reflects system used for this study and not the numbering system of the implant manufacturer. For all but one participant, the standard manufacturer electrode numbers used in the study were 6 (most basal; indicated as “1” for the study), 8, 10, 12, 14, 16 and 18. For F19R, electrodes 7 (most basal; indicated as “1” for the study), 9, 11, 13, 15, 17 and 19 were activated.
Fig. 2Scatterplots relating eCAP amplitudes (normalized, as in Fig. 1) to recording electrode impedance (kΩ) within subjects. The participants are arranged in the same order as in Fig. 1. The normalization amplitude is provided in parentheses below the participant ID at the bottom of each panel. Regression lines and model parameters are displayed in the panels with significant negative correlations between eCAP amplitude and recording electrode impedance (p ≤ 0.05).
Fig. 3Scatterplot relating eCAP amplitudes (μA) to recording electrode impedance (kΩ) across all participants. A unique symbol/color combination is used for each participant.
Fig. 4Scatterplots relating vowel-discrimination scores (percent correct) to suprathreshold eCAP amplitudes. The three methods used to quantify eCAP amplitudes are shown in separate panels. Top panel: across-site mean of the eCAP amplitudes. Middle panel: amplitude for the electrode in the middle of the reduced-channel array. Bottom panel: eCAP amplitude normalized by the recording electrode impedance and averaged across the array. Simple linear regression fits are displayed as solid lines. Chance performance is 10% for this closed-set task (dashed horizontal line).